There are currently 56 active clinical trials seeking participants for Pancreas Cancer research studies. The states with the highest number of trials for Pancreas Cancer participants are California, New York, Texas and Florida.
ctDNA Assay in Patients With Resectable Pancreatic Cancer
NCT05052671
Recruiting
The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may provide preliminary evidence that helps improve future patient care through targeted diagnostics, prognosis, and/or treatment.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
12/12/2023
Locations: University of Oklahoma, Oklahoma City, Oklahoma
Conditions: Pancreas Cancer
Register for Updates
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
NCT05156866
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: Providence St. Jude Medical Center, Fullerton, California +6 locations
Conditions: Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
Register for Updates
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
NCT05159440
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: Providence St. Jude Medical Center, Fullerton, California +6 locations
Conditions: Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
Register for Updates
ExoLuminate Study for Early Detection of Pancreatic Cancer
NCT05625529
Recruiting
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performan... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: University of California, San Diego, La Jolla, California +7 locations
Conditions: Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Register for Updates
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT03484299
Recruiting
Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: University of Louisville, Louisville, Kentucky
Conditions: Pancreas Cancer
Register for Updates
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
NCT04837833
Recruiting
The purpose of this study is to see if ultrasound images that are analyzed by a special computer program can be used to measure the size of PDAC tumors in the liver as accurately as CT scans that involve contrast material (also called contrast-enhanced CT scans). All participants in this study will have pancreatic ductal adenocarcinoma (PDAC) that has spread (metastasized) to the liver, and all participants will be scheduled for a routine CT scan that will measure their cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Pancreas Cancer, Gastrointestinal Adenocarcinoma
Register for Updates
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
NCT05068752
Recruiting
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
10/18/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Pancreas Cancer
Register for Updates
Collection of Circulating Biomarkers in Pancreatic Cancer
NCT05743049
Recruiting
This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pancreas Cancer
Register for Updates
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT04203641
Recruiting
This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/02/2023
Locations: Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona +2 locations
Conditions: Pancreas Cancer
Register for Updates
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
NCT04141995
Recruiting
Purpose: To determine the feasibility and safety of combining digoxin as a modulator of the hypoxia pathway in combination with FOLinic acid, 5-Fluorouracil, IRINotecan and OXaliplatin (FOLFIRINOX) in patients with resectable pancreatic cancer.
Gender:
All
Ages:
19 years and above
Trial Updated:
09/29/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Pancreas Cancer, Adenocarcinoma of the Pancreas
Register for Updates
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
NCT04594772
Recruiting
The purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/14/2023
Locations: University of Arizona, Tucson, Arizona +1 locations
Conditions: Pancreas Cancer
Register for Updates
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
NCT05915351
Recruiting
A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)
Gender:
All
Ages:
18 years and above
Trial Updated:
07/03/2023
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer
Register for Updates